AlphAIalphai — Financial news for AI agents
The Manila TimesFEB 252 min read$CLRB

Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026

Cellectar Biosciences, Inc. announced it will release its full year 2025 financial results and provide a corporate update on March 4, 2026, at 8:30 a.m. Eastern Time. The company will host a conference call and webcast to discuss these results. Cellectar Biosciences is a late-stage clinical biopharmaceutical company developing proprietary drugs for cancer treatment, utilizing its Phospholipid Drug Conjugate™ (PDC) delivery platform.

Original reporting
The Manila Times · GlobeNewswire
Published Feb 25, 2026, 1:23 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Feb 25, 2026, 2:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026 — source image
Source · The Manila Times
Decision brief

The 30-second read

$CLRBNeutralLow
01

Why it matters

The scheduled financial results are unlikely to have a major impact unless accompanied by unexpected news or clinical trial updates.

02

Market read

The event is relevant for biotech investors but is unlikely to cause major market shifts unless unforeseen news occurs.

03

What to watch

Potential regulatory developments or clinical trial news could significantly influence stock price independently of the earnings report.

Timing: short-term (within 1 week) around March 4, 2026

Background

Cellectar Biosciences is a late-stage clinical biopharmaceutical company developing proprietary cancer treatments using its PDC platform.

Company-level read

Ticker impact

$CLRBNeutralMedium confidence
Context

The news pertains to Cellectar Biosciences' upcoming financial report and corporate update, which is relevant for investors and traders interested in biotech and life sciences sectors.

Expected impact

Minimal to no immediate price change expected; potential for slight volatility around the event date.

Evidence & confidence

The event is a scheduled earnings report, which typically leads to moderate volatility. However, as a late-stage clinical biotech with a niche focus, its stock may not experience large swings unless unexpected news emerges.

Market effects

Sector

Potential slight positive sentiment in biotech sector due to scheduled positive earnings reports.

Regional

Limited regional impact; primarily affects US-based biotech stocks.

Global

Low; specific to US biotech sector and company.

Counterpoint

What could challenge this read

The earnings report could surprise positively, leading to a sharp upward movement if results exceed expectations.

Key entities

  • Company
    Cellectar Biosciences

    A biotech company focused on cancer therapeutics using PDC technology.

Read at source← All news

Related articles

AUG 17
$CLRBMed

Cellectar Biosciences Inc (CLRB) (Q2 2026) Earnings Call Highlights: Strong Clinical Data

Cellectar Biosciences (CLRB) reported Q2 2026 results on an earnings call, including $34.0M cash at June 30, 2026, $4.6M R&D expense, and a $6.9M net loss ($0.57/share). Management discussed Phase 3 WM site activation, targeted accelerated-approval submission in March-April 2027, CLR 125 data later in 2026/early 2027, and actinium-225 multi-sourcing. The May financing added $35M upfront plus milestone warrants up to $105M.

yahoo.com7 min
AUG 13
$CLRBMed

Cellectar Reports Q2 2026 Results, Strengthened Cash Positions Supports Oncology Pipeline

Cellectar Biosciences (CLRB) reported Q2 2026 results. Cash and cash equivalents were $34.0M as of June 30, 2026, funding operations into Q2 2027. R&D rose to $4.6M from $2.4M a year earlier; net loss was $6.9M, or $0.57/share. Pipeline progress includes Phase 3 prep for Iopofosine I 131 in Waldenström macroglobulinemia and Phase 1b enrollment for CLR 125 in triple-negative breast cancer.

rttnews.com5 min
AUG 13
$CLRBMed

Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Cellectar Biosciences (NASDAQ: CLRB) reported Q2 2026 results and corporate updates. It initiated site activation for a Phase 3 confirmatory trial of iopofosine I 131 in Waldenström macroglobulinemia, with an NDA planned for mid-2027 under FDA Accelerated Approval. ASCO data showed 79.2% MRR (n=24) post-BTKi. CLR 125 Phase 1b TNBC enrollment began. Cash was $34.0M at June 30, 2026.

finanznachrichten.de7 min
AUG 13
$CLRBMed

Cellectar Biosciences, Inc. (CLRB): Results of Operations and Financial Condition

Cellectar Biosciences, Inc. (CLRB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2623056d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned

SEC EDGAR 8-K6 min
AUG 18
$RKLBMedAI 8/10

Rocket Lab Now Prime and Bus Supplier in GEO: Viasat Selects Lightning-GEO for Anti-Jam Satellite

Rocket Lab was selected by Viasat to supply the satellite bus for Viasat’s U.S. Space Force anti-jam Protected Tactical SATCOM-Global (PTS-G) Swarm 1 spacecraft, using Rocket Lab’s Lightning-GEO platform. Viasat will integrate, operate, and lead the prime role; Rocket Lab builds the bus. The Swarm 1 delivery order totals about $437.7M across contractors; terms were not disclosed.

techtimes.com7 min
AUG 17
$LHXMed

L3Harris ousts CEO Kubasik over conduct violation

L3Harris Technologies said CEO Christopher Kubasik stepped down after a board investigation found misconduct and the company entered a separation agreement. The company did not disclose details, saying the conduct was unrelated to financial reporting or operations. Sam Mehta was named successor. Reuters reported no severance, but he can keep vested options. LHX shares fell.

foxbusiness.com3 min